Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice

References

• Haslam DW, James WP. Obesity. Lancet. 2005;9492:1197–1209.
   Google Scholar
• Report of a WHO consultation. Obesity: preventing and managing the global epidemic; 2000.
   Google Scholar
• World Health Organization. Fact sheets - Obesity and overweight. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed June 9, 2021.
   Google Scholar
• Bassett J. International diabetes I, world health organization regional office for the Western P, international association for the study of O, international obesity T. Asia Pacific Persp. 2000;2000:1.
   Google Scholar
• Nam GE, Kim Y-H, Han K, et al. Obesity fact sheet in Korea, 2020: prevalence of obesity by obesity class from 2009 to 2018. J Obes Metab Synd. 2021;30(2):141–148. doi:10.7570/jomes21056
   PubMed Web of Science ®Google Scholar
• Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American college of cardiology/American heart association task force on practice guidelines and the obesity society. Circulation. 2014;129(25_suppl_2):S102–38. doi:10.1161/01.cir.0000437739.71477.ee
   PubMed Web of Science ®Google Scholar
• Goldstein DJ. Beneficial health effects of modest weight loss. Internat J Obes Rel Metab Dis. 1992;16(6):397–415.
   PubMed Web of Science ®Google Scholar
• Seo MH, Lee WY, Kim SS, et al. Korean society for the study of obesity guideline for the management of obesity in Korea. J Obes Metab Synd. 2018;28(1):40.
   Web of Science ®Google Scholar
• Wing RR, Hill JO. Successful W Eight Lossm Aintenance. Ann Rev Nutrit. 2001;21:323–341. doi:10.1146/annurev.nutr.21.1.323
   PubMed Web of Science ®Google Scholar
• Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Associ. 2007;107(10):1755–1767.
   PubMed Web of Science ®Google Scholar
• Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. Internat J Obes. 2015;39:1188–1196. doi:10.1038/ijo.2015.59
   PubMed Web of Science ®Google Scholar
• Gomez-Arbelaez D, Crujeiras AA-O, Castro AI, et al. Resting metabolic rate of obese patients under very low calorie ketogenic diet. Nutrit Metabol. 2018;15. doi:10.1186/s12986-018-0249-z
   PubMed Web of Science ®Google Scholar
• Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE study group. J Am Med Directors Assoc. 2013;14(8):542–559. doi:10.1016/j.jamda.2013.05.021
   PubMed Web of Science ®Google Scholar
• The Korean Nutrition Society. Dietary reference intakes for Koreans 2020; 2020.
   Google Scholar
• The Korean Nutrition Society. Recommended dietary allowances for Koreans, 7th revision Seoul; 2000.
   Google Scholar
• Kim JAO. Optimal diet strategies for weight loss and weight loss maintenance. J Obesit MetabSynd. 2021;30:20–31. doi:10.7570/jomes20065
   Web of Science ®Google Scholar
• Jung J-G, Kim J-S, Yoon S-J, Lee S, Ahn S-K. Korean alcohol guidelines for primary care physician. KJFP. 2021;11(1):14–21. doi:10.21215/kjfp.2021.11.1.14
   Google Scholar
• Kim B-Y, Kang SM, Kang J-H, et al. 2020 Korean society for the study of obesity guidelines for the management of obesity in Korea. JOMES. 2021;30(2):81–92. doi:10.7570/jomes21022
   Google Scholar
• Smith KB, Smith MS. Obesity Statistics. Primary Care. 2016;43:121–135. doi:10.1016/j.pop.2015.10.001
   PubMed Web of Science ®Google Scholar
• Canuto RA-O, Garcez AA-O, de Souza RA-O, Kac GA-O, Olinto MA-O. Nutritional intervention strategies for the management of overweight and obesity in primary health care: a systematic review with meta-analysis. Obes Rev. 2021;22. doi:10.1111/obr.13143
   PubMed Web of Science ®Google Scholar
• Hall KD, Kahan S. Maintenance of lost weight and long-term management of obesity. Med Clin North Am. 2018;102:183–197. doi:10.1016/j.mcna.2017.08.012
   PubMed Web of Science ®Google Scholar
• Tak YA-O, Lee SY. Long-term efficacy and safety of anti-obesity treatment: where do we stand? Curr Obes Rep. 2021;10:14–30. doi:10.1007/s13679-020-00422-w
   PubMed Web of Science ®Google Scholar
• Blonde LA-O, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Advan Therap. 2018;35:1763–1774. doi:10.1007/s12325-018-0805-y
   PubMed Web of Science ®Google Scholar
• Administration FaD. Guidance for industry on developing products for weight management, 2007 February 15, 2007;National Archives and Records Administration; 2007:7441–7442.
   Google Scholar
• Ko HJ, Kim JW, Lim SA-O. Adherence to and dropout from liraglutide 3.0 mg obesity treatment in a real-world setting. J Obesit Metab Synd. 2022;31:254–262. doi:10.7570/jomes22029
   PubMed Web of Science ®Google Scholar
• Melin I, Reynisdottir S, Fau - Berglund L, et al. Conservative treatment of obesity in an academic obesity unit. Long-term outcome and drop-out. Eat Weig Disord. 2006;11: 22–30. doi:10.1007/BF03327740
   PubMedGoogle Scholar
• Inelmen EM, Toffanello ED, Enzi G, et al. Predictors of drop-out in overweight and obese outpatients. Internat J Obes. 2005;29(1):122–128.
   Web of Science ®Google Scholar
• Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005;75:406–433. doi:10.1016/j.pneurobio.2005.04.003
   PubMed Web of Science ®Google Scholar
• Narayanaswami V, Dwoskin LP. Obesity: current and potential pharmacotherapeutics and targets. Pharmacol Therapeut. 2017;170:116–147.
   PubMed Web of Science ®Google Scholar
• Hendricks EJ, Greenway FL, Greenway FL. How physician obesity specialists use drugs to treat obesity. Obesity. 2009;17:1730–1735. doi:10.1038/oby.2009.69
   PubMed Web of Science ®Google Scholar
• Hampp C, Borders-Hemphill V, Borders-Hemphill V. Use of prescription antiobesity drugs in the United States. Pharmacotherapy. 2013;33:1299–1307. doi:10.1002/phar.1342
   PubMed Web of Science ®Google Scholar
• Márquez-Cruz M, Kammar-García A, Huerta-Cruz JC, et al. Three- and six-month efficacy and safety of phentermine in a Mexican obese population. Internat J Clin Pharmacol Therap. 2021;59(8):539.
   Web of Science ®Google Scholar
• Hendricks EJ, Gupta AK, Westman EC, Gupta AK. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity. 2011;19:2351–2360. doi:10.1038/oby.2011.94
   PubMed Web of Science ®Google Scholar
• Astrup A, Carraro R, Fau - Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Internat J Obes. 2012;36(6):843–854.
   PubMed Web of Science ®Google Scholar
• Ministry of Food and Drug Safety. Principles for safe use of psychotropic appetite suppressant. Narcotics Management Division. Available from: https://www.mfds.go.kr/brd/m_99/view.do?seq=44506. Accessed August 11, 2020.
   Google Scholar
• Ioannides-Demos LL, McNeil JJ, Tonkin AM, McNeil JJ. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf. 2006;29:277–302. doi:10.2165/00002018-200629040-00001
   PubMed Web of Science ®Google Scholar
• Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315:2424. doi:10.1001/jama.2016.7602
   PubMed Web of Science ®Google Scholar
• van Pelt RE, Dinneno FA, Seals DR, Jones PP. Age-related decline in RMR in physically active men: relation to exercise volume and energy intake. Am J Physiol. 2001;281(3):E633–E639.
   Google Scholar
• D’Onofrio G, Kirschner J, Prather H, Goldman D, Rozanski A. Musculoskeletal exercise: its role in promoting health and longevity. Prog Cardiovasc Dis. 2023;77:25–36. doi:10.1016/j.pcad.2023.02.006
   PubMed Web of Science ®Google Scholar
• Lee M, Lauren BA-O, Zhan T, et al. The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity. Obes Sci Pract. 2020;6:162–170. doi:10.1002/osp4.390
   PubMed Web of Science ®Google Scholar
• Sanyal D, Majumdar A. Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting. Ind J Endocrinol Metabol. 2013;17:301. doi:10.4103/2230-8210.119629
   Google Scholar
• van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Internat J Obes. 2014;38(6):784–793.
   PubMed Web of Science ®Google Scholar
• Farr OM, Tsoukas MA, Triantafyllou G, et al. Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: a randomized, placebo-controlled, crossover study. Metabolism. 2016;65(7):945–953.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22. doi:10.1056/NEJMoa1411892
   PubMed Web of Science ®Google Scholar
• Gorgojo-Martínez JA-O, Basagoiti-Carreño B, Sanz-Velasco A, Serrano-Moreno C, Almodóvar-Ruiz F. Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: the XENSOR Study. Internat J Clin Pract. 2019;73. doi:10.1111/ijcp.13399
   PubMed Web of Science ®Google Scholar
• Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017;3:3–14. doi:10.1002/osp4.84
   PubMed Web of Science ®Google Scholar
• Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606–1616. doi:10.1016/S0140-6736(09)61375-1
   PubMed Web of Science ®Google Scholar
• Park JA, Kim JA-O, Choi JH, et al. Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention. Intern J Obes. 2021;45:776–786. doi:10.1038/s41366-021-00739-z
   PubMed Web of Science ®Google Scholar
• Trenson L, Trenson S, van Nes F, et al. Liraglutide for weight management in the real world: significant weight loss even if the maximal daily dose is not achieved. Obesity Facts. 2022;15(1):83–89.
   PubMed Web of Science ®Google Scholar
• Kim KK. Understanding the mechanism of action and clinical implications of anti-obesity drugs recently approved in Korea. Korean J Fam Med. 2019;40:63–71. doi:10.4082/kjfm.19.0013
   PubMed Web of Science ®Google Scholar
• Sharretts J, Galescu O, Gomatam S, Andraca-Carrera E, Hampp C, Yanoff L. Cancer risk associated with lorcaserin - The FDA’s review of the CAMELLIA-TIMI 61 trial. New Engl J Med. 2020;383:1000–1002. doi:10.1056/NEJMp2003873
   PubMed Web of Science ®Google Scholar
• Bohula EA, Wiviott SD, McGuire DK, et al. Cardiovascular safety of lorcaserin in overweight or obese patients. New England Journal of Medicine. 2018;379:1107–1117. doi:10.1056/NEJMoa1808721
   PubMed Web of Science ®Google Scholar
• Heck AM, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy. 2000;20(3):270–279.
   PubMed Web of Science ®Google Scholar
• Karhunen L, Franssila-Kallunki A, Rissanen P, et al. Effects of Orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. Intern J Obes Relat Metab Dis. 2001;24:1567–1572. doi:10.1038/sj.ijo.0801443
   Web of Science ®Google Scholar
• Torgerson JS, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Clin Diabetol. 2004;5(2):95–104.
   Google Scholar
• Henry CJ. Basal metabolic rate studies in humans: measurement and development of new equations. Publ Health Nutrit. 2005;8:1133–1152. doi:10.1079/PHN2005801
   PubMed Web of Science ®Google Scholar
• Leibel RL, Rosenbaum M, Fau - Hirsch J, Hirsch J. Changes in energy expenditure resulting from altered body weight. New Engl J Med. 1995;332:621–628. doi:10.1056/NEJM199503093321001
   PubMed Web of Science ®Google Scholar
• Fothergill E, Guo J, Howard L, et al. Persistent metabolic adaptation 6 years after “The Biggest Loser” competition. Obesity. 2016;24:1612–1619. doi:10.1002/oby.21538
   PubMed Web of Science ®Google Scholar
• Smith SR, Fujioka K, Gupta AK, et al. Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. Diab Obesit Metab. 2013;15(9):863–866. doi:10.1111/dom.12095
   PubMed Web of Science ®Google Scholar
• Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, Phase 3 trial. Lancet. 2011;377(9774):1341–1352. doi:10.1016/S0140-6736(11)60205-5
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183
   PubMed Web of Science ®Google Scholar
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038
   PubMed Web of Science ®Google Scholar